Get started Log in

VIVE — Vivesto AB Share News

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
SEK79.82m
Enterprise Value
SEK56.31m
Revenue

Brief: Vivesto And CEO Francois Martelet Have Agreed On Ending Employment Relationship
13/06/2022 15:31
Brief: Vivesto Q1 Operating Loss Narrows To SEK 26.3 Mln
25/05/2022 07:06
Brief: Vivesto Proposes Peter Zonabend As Chairman
20/04/2022 07:38
Brief: Vivesto Signs Agreement With US Contract Research Services Provider
19/04/2022 06:11
Brief: Preliminary Result Of Oasmia's Rights Issue
24/03/2022 10:01
Brief: Oasmia Signs Manufacturing Agreement With Lonza For Ovarian Cancer Drug Candidate Cantrixil
21/03/2022 08:07
Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
21/03/2022 06:11
Brief: Oasmia Expands Research And Development Ability With Planned Laboratory Upgrade
17/03/2022 06:23
Brief: Oasmia Expands Intellectual Property Portfolio In Key Territories
07/03/2022 06:08
Brief: Oasmia Pharmaceutical Q4 Operating Loss Narrows To SEK 2.1 Mln
24/02/2022 07:22
Brief: Oasmia Says Finds Novel Candidate For Use In XR-18 Platform
24/01/2022 06:01
Brief: Oasmia Announces Intention To Change Name To Vivesto
19/01/2022 06:43
Brief: Oasmia Resolves On Fully Secured Rights Issue Of About SEK 151 Mln
19/01/2022 06:33
Brief: Oasmia Q3 Operating Loss Narrows To SEK 29.6 Mln
18/11/2021 07:16
Brief: Oasmia Announces Global Settlement
21/10/2021 08:07
Brief: Oasmia Pharmaceutical Signs License Agreement With Farmamondo Group
17/09/2021 06:19
Brief: Oasmia Pharmaceutical Q2 Operating Loss Narrows To TSEK 56,165
19/08/2021 07:13
Brief: Oasmia Transfers Nordic Commercialization Rights For Apealea To Inceptua
28/06/2021 06:01
Brief: Oasmia Q1 Operating Loss Narrows To SEK 40.8 Mln
27/05/2021 07:09
Brief: Oasmia Pharmaceutical: Phase 1B Trial Of Docetaxel Micellar Is Granted Ethical Committee Approval
21/04/2021 06:06